FDA approves U.S. FDA-approved midazolam nasal spray for cluster seizures over 12 years of age
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
epilepsy is a chronic neurological disease in the brainIt is the world's fourth-largest neurological disease, affecting the lives of about 65 million peopleIt is estimated that 150,000 people with epilepsy in the United States experience cluster seizurestoday, UCB(http:// announcedthat the U.SFDA(http://approved the company's Nayzilam nasal spray for acute treatment of cluster seizures in people over 12 years of age with epilepsyAbout Nayzilam
Nayzilam is a short-term treatment for cluster seizuresPatients can carry this disposable nasal sprayIt can be used by non-health care professionals in patients with seizuresIts main component is benzodiazepineNayzilam's approval was based on a randomized double-blind, placebo-controlled clinicaltrial (http:// results 201 patients were treated with Nayzilam or a placebo after a cluster seizure results showed that more patients in the Nayzilam group had seizures stopped within 10 minutes of treatment (80.6 percent vs 70.1 percent) At the same time, more patients did not have a recurrence of epilepsy within 10 minutes to 6 hours after the first seizure (58.2% vs 37.3%)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
